Sorry to hear about it.I started it out with elan and bapizumab back in 03 and 13 yrs later, all these drugs that target plaques have failed even though they keep moving up earlier in disease progression. It seems a new hypothesis is needed and I am not really aware of one. May be there is one that involves more agents and causal factors than the beta amyloid.
The primary-endpoint p-value of .095 was disclosed in LLY’s PR on 11/23/16 (#msg-126758415), so the above info is not the main interest in yesterday’s presentation; rather, the main interest is the a-beta biomarker data:
In other words, Sola was successful at removing a-beta, but not in the locations that matter. This is a curious pair of findings that leaves more questions than answers.